Merck & Co doubles up on Ablynx research deal


Cut-down antibody drug developer Ablynx has agreed a second R&D partnership with US Pharma firm Merck & Co. Ablynx will receive €20 million (£17 million) up front, plus up to €10.7 million in research funding over three years. On top of that, milestone payments for any products that emerge from the collaboration could net the Belgian biotech up to €1.7 billion plus royalties.

This collaboration will focus on nanobodies (antibody fragments) directed against cancer, and builds on Merck’s previous collaboration with Ablynx for nanobodies that target voltage-gated ion channels. Ablynx also recently joined forces with Abbvie to develop nanobodies for treating rheumatoid arthritis and systemic lupus erythematosus.


Related Content

Grabbing slices of the immuno-oncology pie

5 August 2015 Business

news image

Another spate of immuno-oncology dealmaking adds to fervour in pharma’s ‘hottest space’

Merck & Co $460m ion channel deal

2 October 2012 Business

news image

Deal with Ablynx relates to antibody fragments

Most Commented

Ethanol to butanol conversion shows sustainable potential

13 January 2016 Research

news image

Borrowed hydrogen chemistry drives reaction to obtain useful fuel from biomass

Israeli chemists urge government to ban chemical weapons

21 July 2016 News and Analysis

news image

Open letter presses prime minister to ‘remove the curse of chemical weapons from the face of the Earth’